Novartis Plays Down Impact Of Split High Court Ruling

Law360, New York (April 1, 2008, 12:00 AM EDT) -- Defending its calls for summary judgment against plaintiffs in multidistrict litigation over its controversial bone cancer drugs, Novartis Pharmaceuticals Corp. has contended that a recent high court decision has no bearing on its argument.

In support of its motion to toss the cases of three Michigan plaintiffs, the drugmaker told the U.S. District Court for the Middle District of Tennessee on Monday that the Supreme Court's 4-4 ruling in Warner-Lambert Co. v. Kent was irrelevant, since the justices were split down the middle and the ruling...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.